Work

PS5-11-03: The value of innovation in breast cancer treatment: Real Option Value of Olaparib for First-Line Treatment of gBRCA1,2 Pathogenic Mutation HR+/HER2-negative and Triple Negative Metastatic Breast Cancer

Year: 2026

Type: article

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-11-03

Authors: C. L. Gong, M. Chavez-MacGregor, D. Elsea, X. Xu, L. Park, S. Katsandres, K. Migliaccio-Walle, D. L. Veenstra

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129425425

FWCI:

Cites:

Cited by:

Related to: